Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06217835
Other study ID # CamiloJcU-Fisio
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date March 20, 2023
Est. completion date September 8, 2023

Study information

Verified date April 2024
Source Camilo Jose Cela University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Gluteus Medius (GM) has also been implicated in the development of Low Back Pain (LBP). GM is one of the main pelvic, where he actively participates in control of motion in the frontal and transverse plane, and hip , improving stability to the lumbopelvic-hip complex. The aim of present study was to investigate whether modifying lower limb length with a different foot insoles of 0.5, 1 and 1.5 cm in a normal population has an effect on ES and GM activity and as a consequence in LBP. As a secondary objective, in turn, to evaluate whether ES and GM activity has an effect on jumping ability as assessed through CMJ.


Description:

Background: Length leg discrepancy (LLD), regardless of its origin, is a very common pathology that can contribute to low back pain. Various authors point out its relationship with the lack of activation of both the gluteus medius (GM) and the ipsilateral erector spinae (ES). The purpose of this study was to identify the activation of Es and GM with different simulated LLD, correlating said activation with the LBP. In turn, to evaluate whether ES and GM activity has an effect on jumping ability as assessed through CMJ. (2) Method: a sample of healthy subjects was selected to whom an artificial LLD was incorporated through a 0.5, 1 and 1.5 cm insole, measuring with EMGs in these 3 moments while walking and performing a counter movement jump (CMJ). The measurement was carried out in random order, in terms of insole height, using a Latin Square. Muscle activation patterns were recorded for 30 seconds at each of the insole heights while walking at 5.7 km/h and compared with the maximum voluntary contraction (MVC), both on the ipsilateral and contra-lateral sides. These muscles were then measured under the same circumstances during the development of the CMJ. (3)


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date September 8, 2023
Est. primary completion date June 3, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Exclusion Criteria: - The volunteers had no problems in range of motion of joints of the lower limbs - pelvic obliquity due to a functional leg length discrepancy. - obesity with body mass index (BMI) 35 > kg/m²

Study Design


Related Conditions & MeSH terms


Intervention

Other:
To evaluate the response of an orthopedic insole
To evaluate the response of an orthopedic insole of different heights on gait.
evaluate activation of musculature
To evaluate the response caused by an orthopedic insole of different heights on the indicated musculature.

Locations

Country Name City State
Spain Juan Hernández Lougedo Villanueva De La Cañada Madrid

Sponsors (1)

Lead Sponsor Collaborator
Camilo Jose Cela University

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Height CMJ CMJ jump flight height 1 week
Primary Height DJ LEFT Flying height in drop jump left leg 1 week
Primary Height DJ RIGHT Flying height in drop jump right leg 1 week
Primary Gluteus medius (mv) Gluteus medius activation (mv) 1 week
Primary Erector Spinae (mv) Erector Spinae activation (mv) 1 week
See also
  Status Clinical Trial Phase
Not yet recruiting NCT01702870 - Diagnostic Accuracy of MR in Myositis N/A
Completed NCT03406780 - A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy Phase 2
Completed NCT01826487 - Phase 3 Study of Ataluren in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Phase 3
Terminated NCT02090959 - An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy Phase 3
Recruiting NCT05126758 - A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy Phase 3
Completed NCT03179631 - Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy Phase 3
Completed NCT05730842 - Absorption, Metabolism, Excretion and Absolute Bioavailability of EDG-5506 in Healthy Volunteers Phase 1
Recruiting NCT06228742 - Molecular Mechanisms Underlying Anabolic Resistance to Protein Intake During Muscle Disuse N/A
Recruiting NCT06289608 - Bruxism and Underlying Psichological Factors
Active, not recruiting NCT05479981 - Extension of AOC 1001-CS1 (MARINA) Study in Adult Myotonic Dystrophy Type 1 (DM1) Patients Phase 2